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Background: Acute-on-chronic liver failure (ACLF) is a common serious hepatitis B virus (HBV)-related disease and
has a poor prognosis. Until recently, initial combination antiviral treatment in ACLF patients was rarely reported.
This study evaluated the effect of initial combination treatment with lamivudine and adefovir dipivoxil on the
prognosis of HBV-related ACLF.
Methods: In this retrospective study, 131 eligible ACLF patients, including 61 treated with 100 mg lamivudine and
10 mg adefovir dipivoxil daily and 70 not treated with any nucleoside analogs (NAs), were selected and assigned
into the NA and non-NA groups. All the patients received standard medicinal therapy. At weeks 0–4 and 12, serum
markers for hepatic and renal functions were measured in all patients and accumulated fatality rates were calculated.
Statistical analyses, including Student’s t test, χ2 test and unconditional logistic regression analysis, were performed
using SPSS version 17.0 software.
Results: Clinical data indicated that improvement of hepatic function was better in the NA than in the non-NA group.
The accumulated fatality rate in the NA group was lower than in the non-NA group at weeks 2–4 and 12, and
these differences were significant. Univariate analysis showed that age, prothrombin activity, model of end-stage
liver disease (MELD) score, and treatment without NAs were risk factors for short-term survival of ACLF. Further research
by unconditional logistic regression analysis identified that older age, high MELD score and treatment without NAs
were independent risk factors for short-term survival of ACLF.
Conclusions: Initial combination antiviral treatment is effective in decreasing short-term fatality of HBV-related ACLF.
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Chronic hepatitis B virus (HBV) infection is a major public
health problem worldwide. According to estimation of the
World Health Organization, about 400 million people are
chronically infected with HBV and ~1 million die from
HBV-related diseases each year [1, 2]. Chronic HBV infec-
tion leads to several related liver diseases, including chronic
hepatitis B, cirrhosis, hepatocellular carcinoma (HCC), and
liver failure [3]. Acute-on-chronic liver failure (ACLF), de-
fined in 1995 as a condition in which acute and chronic* Correspondence: 18990283956@163.com
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creativecommons.org/publicdomain/zero/1.0/liver disease occur simultaneously, is a common serious
HBV-related liver disease and causes acute deterioration of
liver function [4]. ACLF has poor prognosis [5, 6].
There is no standard treatment for ACLF. The curative
effect of standard medical treatment is limited and the
fatality rate is high [7–9]. Clinical application of an
artificial liver support system can temporarily improve
patients’ condition. However, it is not effective in
decreasing fatality rate [10–13]. Although liver trans-
plantation is effective for ACLF, its clinical application is
hindered by the difficulty in finding suitable donors and
its high cost [14, 15]. Thus, a new treatment to improve
prognosis is eagerly required in clinical practice.cle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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mains obscure, growing evidence suggests that viral fac-
tors [16–18], host factors [19–21], and their interactions
determine the outcome of ACLF. HBV DNA replication
is an important factor for deterioration of liver function
and closely associated with the risk of HCC.
Nucleoside analogues (NAs) can inhibit the replication
of HBV and decrease serum HBV DNA loads, leading
to improvement of liver function and reduction of cir-
rhotic complications and occurrence of HCC [22–24].
Treatment with one NA alone is unsatisfactory, although
monotherapy can improve patients’ condition and de-
crease short-term and long-term fatality rates [7–9]. Pre-
vious research has suggested that initial combination
antiviral therapy with lamivudine and adefovir dipivoxil
is more effective than monotherapy in decreasing serum
HBV load and improving prognosis [25, 26]. Until re-
cently, initial combination antiviral therapy in ACLF pa-
tients was rarely reported. ACLF develops rapidly and
has poor prognosis, and combination antiviral therapy is
more effective than monotherapy [25, 26]. Therefore, in
the present study, 61 patients were treated with 100 mg
lamivudine and 10 mg adefovir dipivoxil daily and 70
were not treated with any NA. Patients were selected to
assess the effect of initial combination antiviral therapy
on clinical condition and short-term survival of ACLF.
Results
Baseline characteristics
As mentioned above, 131 eligible ACLF patients were re-
cruited and divided into NA and non-NA groups. There
were no significant differences in the baseline characteris-
tics of age, sex, hepatitis B e antigen (HBeAg) status, model
of end-stage liver disease (MELD) score, and baseline
levels of serum HBV DNA load, total bilirubin (TBIL),
albumin, alanine aminotransferase (ALT), international
normalized ratio (INR), prothrombin activity (PTA) and
creatinine between the two groups (Table 1).Table 1 Baseline characteristics of the patients
NA group (mean ± SD)
Male (%) 52 (85.25)
HBeAg positive (%) 19 (31.15)
Age (yr) 40.31 ± 10.75
HBV DNA log10 (copies/ml) 5.72 ± 1.38
TBIL (μmol/L) 278.56 ± 116.09
Albumin (g/L) 34.73 ± 5.85
ALT (U/L) 1037.44 ± 823.50
PTA (%) 31.15 ± 9.71
Creatinine (μmol/L) 66.01 ± 12.46
MELD Score 22.82 ± 2.99Serum TBIL, ALT, albumin and PTA at different times of
therapy
Baseline serum TBIL, ALT, albumin and PTA did not
differ significantly between the NA and non-NA groups.
Serum TBIL levels increased at week 1, decreased below
baseline levels at week 2, and then continued to decrease
in the NA group (Table 2). In the non-NA group, serum
TBIL levels continued to increase, reached a peak at
week 2, and then began to decrease. Serum TBIL levels
were lower in the NA group than non-NA group at
weeks 1–4 and these differences were significant at
weeks 2 and 3 (t = 4.52, P < 0.001; t = 3.59, P = 0.001)
(Table 2). In the NA group, serum albumin levels con-
tinued to increase. In the non-NA group, serum albumin
levels decreased below baseline levels at week 1 and then
fluctuated at weeks 2–4. Serum albumin levels were
higher in the NA group than non-NA group at weeks 1–4
and theses differences were significant (t = 3.67, P < 0.001;
t = 3.92, P < 0.001; t = 5.77, P < 0.001; t = 3.88, P < 0.001)
(Table 2). Although serum PTA levels continued to in-
crease in the NA and non-NA groups, it increased more
rapidly in the NA group, and serum PTA levels were
higher in the NA than non-NA group at weeks 1–4. These
differences were significant at weeks 2 and 3 (t = 2.52,
P = 0.013; t = 2.38, P = 0.020). Serum ALT levels continued
to decrease in these two groups although the differences
between the groups were not significant. There was no
patient with abnormal serum creatinine and urea nitrogen
levels in either group until week 12.
Accumulated fatality rates in the two groups
All ACLF patients in these two groups were followed up
to week 12. At week 12, 55 patients were dead and the
fatality rate was 41.98 %. Accumulated fatality rate at
weeks 2–4 and 12 in the NA group was 1.64 % (1/61),
14.75 % (9/61), 21.31 % (13/61) and 24.59 % (15/61), re-
spectively. In the non-NA group, accumulated fatality rate
was 21.43 % (15/70), 35.71 % (25/70), 47.14 % (33/70) andNon-NA group (mean ± SD) t or χ2 value P value
59 (84.29) 0.02 0.88
18 (25.71) 0.48 0.49
43.14 ± 10.37 -1.53 0.13
5.31 ± 1.56 1.53 0.13
260.24 ± 115.50 0.90 0.37
34.35 ± 4.49 0.42 0.67
833.93 ± 794.70 1.44 0.15
33.34 ± 10.20 -1.25 0.21
76.94 ± 52.23 -1.70 0.09
23.95 ± 5.91 -1.40 0.17
Table 2 Time-dependent changes of serum TBIL, ALT, albumin and PTA
Serum marker Time NA group Non-NA group t value P value
TBIL (μmol/L) Week 1 310.98 ± 134.94 360.39 ± 122.11 1.95 0.054
Week 2 272.74 ± 166.83 427.22 ± 189.74 4.52 <0.001
Week 3 239.22 ± 172.03 379.72 ± 200.63 3.59 0.001
Week 4 240.55 ± 210.19 299.47 ± 195.52 1.10 0.28
ALT (U/L) Week 1 224.43 ± 234.97 267.75 ± 242.43 -0.93 0.36
Week 2 120.20 ± 116.55 122.05 ± 89.96 -0.09 0.93
Week 3 87.31 ± 74.70 73.96 ± 38.98 1.02 0.31
Week 4 63.62 ± 49.75 57.48 ± 28.60 0.56 0.58
Albumin (g/L) Week 1 35.31 ± 5.09 32.05 ± 3.74 3.67 <0.001
Week 2 36.78 ± 5.02 33.37 ± 3.78 3.92 <0.001
Week 3 37.51 ± 5.41 32.39 ± 2.90 5.77 <0.001
Week 4 37.38 ± 5.21 32.42 ± 4.41 3.88 <0.001
PTA (%) Week 1 52.77 ± 27.31 45.59 ± 24.93 1.34 0.18
Week 2 57.85 ± 29.73 44.31 ± 23.20 2.52 0.013
Week 3 65.58 ± 30.56 49.70 ± 27.53 2.38 0.020
Week 4 58.23 ± 31.56 48.50 ± 24.78 1.14 0.260
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accumulated fatality rates in the NA group were lower than
in the non-NA group and these differences were signifi-
cant (χ2 = 11.91, P = 0.001; χ2 = 7.45, P = 0.006; χ2 = 9.55,
P = 0.002; χ2 = 14.18, P < 0.001). This indicated that anti-
viral therapy may decrease short-term fatality rate.
Factors influencing short-term survival of ACLF
Univariate analysis was performed to identify risk factors
for short-term survival of ACLF patients. Age, PTA,
MELD score and treatment without NAs were risk fac-
tors for short-term survival of ACLF patients (t = 3.06,
P = 0.003; t = 2.05, P = 0.042; t = 3.49, P = 0.001; χ2 = 14.18,
P < 0.001) (Table 3). Multivariate analysis using uncondi-
tional logistic regression was performed to identify inde-
pendent risk factors for short-term survival of ACLFTable 3 Univariate analysis of risk factors for the survival of ACLF pa
Related factors Survivor (n = 76) (Mean ± SD)
Male (%) 64 (84.21)
HBeAg positive (%) 19 (25.00)
Treatment without NAs (%) 30 (39.47)
Age (yr) 39.49 ± 10.50
HBV DNA log10 (copies/ml) 5.52 ± 1.40
TBIL (μmol/L) 271.33 ± 111.05
Albumin (g/L) 34.67 ± 5.44
ALT (U/L) 912.92 ± 861.61
PTA (%) 33.81 ± 9.40
Creatinine (μmol/L) 66.66 ± 14.74
MELD Score 22.11 ± 2.84patients and P ≥ 0.05 was selected as the exclusion criter-
ion. Sex, age, HBeAg status, HBV DNA loads, MELD
score, serum TBIL level, ALT level, albumin level and
PTA level, and treatment without NAs were included in
the unconditional regression analysis. Unconditional lo-
gistic regression analysis showed that age, MELD score
and treatment without NAs were independent risk factors
for short-term survival of ACLF [P = 0.007, odds ratio
(OR) = 1.063, 95 % confidence interval (CI): 1.017–1.112;
P = 0.002, OR = 1.201, 95 % CI: 1.068–1.351; P = 0.001,
OR = 4.717, 95 % CI: 1.967–11.315) (Table 4).
Discussion
ACLF is a serious liver disease caused by multiple factors,
with impairment of several major liver functions, including
synthetic function, detoxification and metabolic regulation.tients
Non-survivor (n = 55) (Mean ± SD) t or χ2 value P value
47 (85.45) 0.04 0.85
18 (32.73) 0.94 0.33
40 (72.73) 14.18 <0.001
45.05 ± 9.96 3.06 0.003
5.50 ± 1.60 0.08 0.94
265.23 ± 122.78 0.30 0.77
34.34 ± 4.77 0.37 0.71
950.50 ± 744.03 0.26 0.80
30.21 ± 10.50 2.05 0.042
79.03 ± 57.78 1.55 0.13
25.24 ± 6.19 3.49 0.001
Table 4 Multivariate analysis of risk factors for the survival of ACLF patients
Related factors Regression coefficient (B) Standard error Wals P OR value 95 % CI
Age (yr) 0.061 0.023 7.355 0.007 1.063 1.017-1.112
Treatment without NAs 1.551 0.446 12.077 0.001 4.717 1.967-11.315
HBV DNA log10 (copies/ml) 0.310 0.164 3.584 0.058 1.363 0.989-1.879
MELD score 0.183 0.060 9.356 0.002 1.201 1.068-1.351
Cons -9.717 2.306 17.761 <0.001 - -
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bleeding, hepatic encephalopathy, and hepatorenal syn-
drome [5]. Fatality rate of ACLF is high and the prognosis
of ACLF is poor [6].
Previous research has revealed that HBV replication
and high serum HBV load are key factors for severe im-
pairment of liver function and associated with rapid dis-
ease progression of ACLF. Previously research revealed
that antiviral treatment of ACLF could effectively de-
crease fatality rate and improve patients’ quality of life
[27]. A study from Taiwan suggested that antiviral ther-
apy increases short-term survival rate of ACLF at the
early stage of liver failure, although it is not able to in-
creases short-term survival rate of ACLF at the late stage
of liver failure. Antiviral treatment as early as possible is
more effective in represses viral replication, preventing
deterioration of clinical condition and improving prognosis
of ACLF. Lamivudine has been proven effective in inhibit-
ing viral replication, improving biochemical and histology,
and reducing the inflammatory response. Lamivudine
treatment has been shown useful for the patients with
HBV-related ACLF [28]. Adefovir dipivoxil, a phosphonate
nucleoside analog of AMP, represses polymerase activity of
HBV [23, 29], and suppresses replication of wild-type and
lamivudine-resistant HBV. Previous research has suggested
that combination antiviral treatment with lamivudine and
adefovir dipivoxil is more effective at decreasing serum
HBV load in chronic hepatitis B patients than using one
nucleoside [25, 26]. ACLF usually develops rapidly, and pa-
tients are in poor condition and have a poor prognosis. Ini-
tial combination antiviral treatment with lamivudine and
adefovir dipivoxil can improve prognosis of ACLF through
repression HBV replication rapidly and effectively. Until
recently, initial combination antiviral treatment in ACLF
patients has rarely been reported. This prompted us to
investigate the effect of initial combination antiviral
treatment with lamivudine plus adefovir dipivoxil in
ACLF patients.
In our study, the TBIL, ALB and PTA were significant
improved at 1 week to 4 week in the NA group. While
in the non-NA group, the TBIL, ALB and PTA were not
effectively improved as the duration of treatment. Previous
research showed that the 3-month accumulated fatality
rate in patients treated with entecavir, lamivudine andnon-NAs was 51.51 %, 50 % and 59.46 %, respectively.
The difference in 3-month accumulated fatality rate be-
tween patients treated with NAs or not was not significant
[7]. Another research reported that the 3-month accumu-
lated fatality rate in patients treated with entecavir, lami-
vudine and non-NAs was 30.95 %, 40 % and 64.71 %,
respectively [8]. In this study, patients treated with NAs
had a significantly lower accumulated fatality rate than pa-
tients treated without NAs. Our research suggested that
the accumulated fatality rates in the NA group were lower
than in the non-NA group at weeks 2–4 and 12, and that
these differences were significant. The 12-week accumu-
lated fatality rate was 24.59 % and 57.14 % in the NA and
non-NA group, respectively. In our study,univariate ana-
lysis showed that age, MELD score, PTA and treatment
without NAs were risk factors for short-term survival of
ACLF patients. Multivariate analysis by unconditional lo-
gistic regression suggested that age, MELD score and
treatment without NAs were independent risk factors for
fatality rate at short-term in ACLF patients. Our results
showed that initial combination antiviral treatment signifi-
cantly decreased short-term accumulated fatality rate of
ACLF patients. It is likely that initial combination antiviral
treatment with lamivudine plus adefovir dipivoxil may be
more effective in inhibiting HBV replication, decreasing
serum HBV DNA loads, lessening inflammation impair-
ment in hepatic tissue, and improving prognosis.
Our study has potential weakness. First, our research
is a retrospective research during May 2006 to June
2011. At that time, lamivudine and adefovir dipivoxil are
the most widely used nucleoside analogues in China. So,
our study only investigated the initial antiviral treatment
with lamivudine plus adefovir dipivoxil. In the future, we
should investigate antiviral treatment effect of other
nucleoside analogues such as tenofovir, entecavir and
telbivudine in ACLF patients. Second, the sample size
of our research is relatively small. Next step, we should
verify our results in a large sample size.
Conclusions
Our results revealed that initial combination antiviral
treatment with lamivudine plus adefovir dipivoxil is able
to improve biochemical parameters, increase PTA and
decreased short-term fatality rate of ACLF patients.
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Patients
ACLF was diagnosed according to “Diagnostic and
Treatment Guidelines for Liver Failure (2012 version)”
recommended by the Chinese Medical Association [4].
The inclusion criteria were as follows: (1) age 18–65
years; (2) hepatitis B surface antigen (HBsAg) positive
for >6 months; (3) serum HBV DNA level >3 log10
copies/ml; (4) recent development of increasing jaundice
(serum bilirubin concentration >171 μmol/l) and decreas-
ing plasma PTA (≤40 %) or INR >1.5; and (5) recent devel-
opment of complications such as hepatic encephalopathy,
abrupt and obvious increase in ascites, spontaneous bac-
terial peritonitis, or hepatorenal syndrome.
Patients affected by other viral hepatitis, alcohol hepatitis,
autoimmune hepatitis, drug-induced hepatitis, primary liver
cancer and hepatorenal syndrome were excluded. Patients
with jaundice caused by obstructive or hemolytic diseases
or prolonged prothrombin time induced by blood system
diseases were also excluded.
A total of 131 eligible HBV-related ACLF patients were
included in our retrospective study. Seventy patients hos-
pitalized in the Department of Infectious Diseases, People’s
Hospital of Deyang City from May 2006 to January 2009,
were not treated with NAs and assigned to the non-NA
group. Sixty-one patients hospitalized from February 2009
to June 2011 were treated with lamivudine plus adefovir
and assigned to the NA group. No patients were previ-
ously treated with nucleoside analogues and interferon.
Our study protocol conformed to the ethical guidelines of
the 1975 Declaration of Helsinki and was approved by the
Ethics Committee of People’s Hospital of Deyang City.
Treatment schedule
All patients received standard medical treatment, including
supply of energy, fresh plasma and albumin, maintenance
of water, electrolyte and acid–base equilibrium, promoting
growth of hepatic cells, anti-inflammatory and antioxidant
treatments, and liver protection methods. Patients with
spontaneous peritonitis received anti-infective therapy
using third-generation cephalosporins. Besides standard
internal medical therapy, patients in the NA group received
initial combination antiviral treatment with lamivudine
(100 mg daily) (GlaxoSmithKline, Greenford, UK) plus
adefovir dipivoxil (10 mg daily) (GlaxoSmithKline) within
24 h after hospitalization.
Measurement of serum markers
Serum markers reflecting hepatocyte damage, including
serum ALT, albumin, TBIL, and creatinine, were assayed
by colorimetry (Hitachi 7180; Hitachi, Tokyo, Japan). Serum
HBV markers, including HBsAg, hepatitis B surface anti-
body, HBeAg, hepatitis B e antibody and hepatitis B core
antibody, were detected by time-resolved fluorescenceimmunoassay (Tailai-II, Fenghua, Guangzhou, China). PTA
was measured by solidification method and INR was calcu-
lated according to the manufacturer’s instructions (Sysmex
CA 7000; Sysmex, Kobe, Japan). Serum HBV DNA load
was quantified by Quantitive Diagnostic Kit for Hepatitis B
Virus DNA (Qiagen, Shenzhen, Guangdong, China). The
MELD score was calculated using the equation: MELD
score = 3.78 × ln [total bilirubin (mg/dL)] + 11.2 × ln
INR + 9.57 × ln [creatinine (mg/dL)] + 6.43 [30].
Follow-up
Patients were followed up at weeks 1–4 and 12. Clinical
and laboratory data and adverse events were recorded.
Statistical analyses
Statistical analyses, including Student’s t test, χ2 test and
unconditional logistic regression, were performed by
SPSS version 17.0. P < 0.05 was considered statistically
significant.
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